Figure 6.
CD33/CD123 NANOBODY TCE exhibits antileukemic effects in a MOLM-13 AML xenograft mouse model. NSG mice were engrafted with 10E6 MOLM-13-Luc AML cells followed by 10E7 human T cells 1 day later. Mice were treated with TCE compounds at the indicated doses between days 2 and 13 of the experiment (QDx10 for CD123 TCE and Q2Dx5 for CD33/CD123 TCE) (A). Panel B illustrates antitumor activity of indicated TCE and doses corroborated by longitudinal quantitation of photon flux using in vivo bioluminescence imaging for global (C) and long-bone (D) tumor growth. Terminal ex vivo bioluminescence imaging analyses were performed of soft tissues spleen, liver, and ovaries to detect tumor cells (E). ∗∗P < .005 in comparison to untreated animals obtained using a two-way ANOVA performed on bio-layer interferometry signal changes from baseline of log values followed by Tukey test.

CD33/CD123 NANOBODY TCE exhibits antileukemic effects in a MOLM-13 AML xenograft mouse model. NSG mice were engrafted with 10E6 MOLM-13-Luc AML cells followed by 10E7 human T cells 1 day later. Mice were treated with TCE compounds at the indicated doses between days 2 and 13 of the experiment (QDx10 for CD123 TCE and Q2Dx5 for CD33/CD123 TCE) (A). Panel B illustrates antitumor activity of indicated TCE and doses corroborated by longitudinal quantitation of photon flux using in vivo bioluminescence imaging for global (C) and long-bone (D) tumor growth. Terminal ex vivo bioluminescence imaging analyses were performed of soft tissues spleen, liver, and ovaries to detect tumor cells (E). ∗∗P < .005 in comparison to untreated animals obtained using a two-way ANOVA performed on bio-layer interferometry signal changes from baseline of log values followed by Tukey test.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal